Quickly verify claims by accessing the underlying experimental data and figures.
Press Enter ↵ to solve
Fuel Your Discoveries
"If you thought that science was certain - well, that is just an error on your part."
- Richard Feynman
Quick Explanation
Copied
Fairburn & Harrison (2003) – Eating disorders
Transdiagnostic synthesis: common core psychopathology across anorexia nervosa (AN), bulimia nervosa (BN), and atypical eating disorders; strong evidence for CBT in BN; limited/uncertain evidence for AN and EDNOS; substantial genetic contribution with ongoing debates on magnitude and mechanisms.
Key limitation: as a 2003 narrative Seminar, it aggregates heterogeneous studies with evolving diagnostic criteria and does not provide new primary datasets.
See primary source:
Long Explanation
Paper Review (Visual): Eating disorders
Source:
Style note: Numbers shown below are taken directly from the provided paper text excerpts; if a value is not explicitly stated, it is not plotted.
1) What the paper claims (tight, evidence-tied)
Transdiagnostic core: AN and BN share “overevaluation of shape and weight,” which drives many secondary features; patients judge self-worth largely/exclusively by shape/weight.
BN defining mechanism: BN is distinguished by recurrent binge eating punctuating attempts to restrict intake, with typical binge amounts described as ~1000–2000 kcal (4.2–8.4 MJ).
Course/outcome heterogeneity in AN: The paper emphasizes multiple trajectories, including a reported 10–20% intractable/unremitting course (as stated in the text).
Genetic contribution (but magnitude debated): The Seminar argues for substantial genetic predisposition to both AN and BN, but highlights uncertainty/variation in heritability estimates—especially for BN—due to study design and diagnostic-criteria changes.
Neurobiology (serotonin emphasis): It reports that some serotonin (5-HT) function abnormalities persist after recovery, and connects dieting changes to serotonergic changes as a possible precipitating mechanism in vulnerable women (as framed by the Seminar).
Treatment evidence gradient: For BN, a “specific form of cognitive behaviour therapy” is described as the most effective treatment, with antidepressants having an antibulimic effect but typically less than CBT and sometimes not sustained; for AN/atypical EDs, evidence is described as limited/tentative.
2) Visual evidence map (from explicit numbers in the paper text excerpt)
These charts are built only from values explicitly present in the provided paper text excerpts.
Note: the excerpt provides 1–2% (range). The bar uses 1.5% purely for display; range is labeled as text above the bar.
The excerpt lists incidence for females and males as 19 and 2 per 100,000 per year (for anorexia nervosa panel text).
The provided text excerpt explicitly reports an anorexia nervosa standardized mortality ratio (SMR) “about 10” over the first 10 years from presentation. It does not provide SMR numerical values for BN or BED within the excerpt you provided, so only AN is plotted below.
3) Treatment evidence summary (explicit claims from the Seminar)
A compact “what is robust vs uncertain” view derived from the text excerpt.
Domain
Claim in Seminar
Evidence strength (as presented)
Critical caveat
Bulimia nervosa (BN) — CBT
Specific CBT is the most effective treatment; ~20 sessions over ~5 months; about a third to half reach complete lasting recovery on intent-to-treat analyses.
“Robust findings” (Seminar framing)
Seminar notes many trials are efficacy rather than effectiveness; real-world uptake is low.
BN — antidepressants
Antidepressants reduce binge/purge quickly and improve mood, but less than CBT; limited evidence suggests effects may not be sustained.
Moderate/less robust than CBT (Seminar framing)
Sustained benefit uncertainty is explicitly raised.
AN & atypical EDs
Few RCTs; recommendations “tentative” and guided by mainstream opinion rather than strong trial evidence.
Uncertain / limited
Heterogeneity and diagnostic ambiguities can dilute signal.
All treatment-evidence statements above are taken from the Seminar’s explicit narrative and table discussion in the provided text excerpt.
4) Scientific quality critique (skeptical but fair)
Strength: The paper is internally consistent: it ties classification to shared core psychopathology, then uses that to motivate a transdiagnostic approach.
Strength: It explicitly acknowledges interpretational caveats for genetic estimates (e.g., diagnostic-criteria broadening and limited power for shared environment effects).
Major limitation: It is a narrative Seminar (not a primary meta-analysis) and therefore cannot quantify publication bias or heterogeneity in effect sizes the way systematic quantitative syntheses do; the Seminar instead provides qualitative “robust vs tentative” judgments.
Diagnostic-era confounding: The paper highlights that classification systems (including EDNOS/“atypical”) leave a large fraction of clinical cases under a residual category; this complicates cross-study comparisons and could distort etiologic inferences.
Neurobiology caution: The serotonin findings are discussed with an important mechanistic uncertainty: many abnormalities may be secondary to malnutrition/weight loss, and trait vs state causality is not definitively established in the Seminar.
Reproducibility limitation: There is no new dataset, code, or primary experimental method to reproduce from the Seminar itself; reproducibility would depend on whether the underlying cited studies can be obtained and reanalyzed.
5) Disproof targets (what would change the Seminar’s central picture?)
Genetic architecture: Large-scale, population-based designs that do not rely on clinic samples and that use stable diagnostic definitions would be required to settle heritability magnitude debates noted by the Seminar.
Shared mechanisms across categories: If longitudinal work showed that the residual “atypical/EDNOS” group did not share core mechanisms with AN/BN (despite symptom overlap and migration), that would weaken the transdiagnostic common-mechanism rationale.
Treatment causality: Effectiveness would need confirmation in routine clinical settings. The Seminar itself notes trial-to-practice generalizability and uptake gaps.
Biological/biomarker emphasis (what’s “known vs uncertain” in this Seminar)
Known (in the Seminar framing): Serotonergic abnormalities (5-HT/5-HT2A receptor-related) have been reported and may persist after recovery in some findings; many neurobiological differences are secondary to malnutrition/weight loss, but persistence is taken as suggestive.
Uncertain: Whether these neurobiological differences are causal trait markers vs epiphenomena remains speculative (trait monoamine abnormality is discussed as speculation).
Next actions in BGPT
Optional: run an independent science agent
Author reviews
Feedback:
Updated: April 19, 2026
BGPT Paper Review
Study Novelty
80%
As a 2003 Lancet Seminar, it coherently advances a transdiagnostic CBT-centered framework and synthesizes genetics/neurobiology/clinical features into one narrative; novelty is moderate-high but not unprecedented in eating-disorder theorizing.
Scientific Quality
80%
Scientifically strong as a synthesis with explicit caveats (e.g., diagnostic-criteria changes, twin-study power limits, state vs trait neurobiology uncertainty). Main quality limitation is the lack of primary quantitative meta-analytic reanalysis and dataset/code for direct reproducibility.
Study Generality
70%
Provides broad conceptual coverage (classification, epidemiology, genetics, neurobiology, management) but grounded in an older diagnostic framework and mainly reflects evidence availability up to its 2003 publication window.
Study Usefulness
90%
High value for understanding core psychopathology, the evidence gradient for BN vs AN, and specific research/service gaps; also offers a mechanistic “state vs trait” caution useful for designing downstream studies.
Study Reproducibility
60%
Reproducible at the level of interpretive claims as presented, but not reproducible in the computational sense: it provides no primary dataset and relies on diverse underlying studies without reanalysis code.
Explanatory Depth
80%
Goes beyond symptom lists to connect core psychopathology to trajectories, genetics, and serotonergic findings while explicitly flagging mechanistic uncertainty (secondary effects vs trait markers).
Build a simple data table from the Seminar’s explicit numeric excerpts (prevalence, incidence, mortality SMR) and render Plotly charts comparing the reported epidemiologic signals across groups.
Get emailed when your analysis is done!
We'll email you the results when your analysis is finished.
Hypothesis Graveyard
“Overvaluation of shape/weight is sufficient to explain eating-disorder onset.” This is unlikely as an explanation because the Seminar positions overvaluation as a core driver but emphasizes complex, not fully understood causal interactions and developmental heterogeneity.
“Neurobiological abnormalities are always primary causes rather than consequences of malnutrition.” The Seminar explicitly notes many abnormalities are likely secondary, so a purely primary-cause model is disfavored by the paper’s own framing.
Quick Explanation
Long Explanation
Top Data Sources
ExportMCP
Keep Exploring
Analysis Wizard
Hypothesis Graveyard
Potential Experiments
Discussion
Fuel Your Discoveries
Ask a Follow-Up
Key Insight